HC Wainwright Equities Analysts Increase Earnings Estimates for Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright upped their Q2 2024 earnings estimates for shares of Entrada Therapeutics in a report issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.06). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.87) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS and FY2025 earnings at ($3.77) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $1.06. Entrada Therapeutics had a net margin of 14.42% and a return on equity of 9.73%. The firm had revenue of $59.12 million during the quarter, compared to analysts’ expectations of $25.00 million.

Entrada Therapeutics Stock Performance

TRDA stock opened at $14.25 on Thursday. The business has a 50-day simple moving average of $14.58 and a two-hundred day simple moving average of $14.30. The company has a market capitalization of $481.08 million, a P/E ratio of 22.62 and a beta of -0.23. Entrada Therapeutics has a 52-week low of $10.75 and a 52-week high of $18.44.

Insider Activity

In related news, insider Natarajan Sethuraman sold 9,675 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $15.19, for a total transaction of $146,963.25. Following the completion of the sale, the insider now owns 190,052 shares in the company, valued at $2,886,889.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Entrada Therapeutics news, Director Peter S. Kim bought 2,600 shares of Entrada Therapeutics stock in a transaction dated Monday, April 8th. The stock was bought at an average cost of $13.57 per share, with a total value of $35,282.00. Following the completion of the acquisition, the director now directly owns 62,936 shares in the company, valued at approximately $854,041.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Natarajan Sethuraman sold 9,675 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $15.19, for a total value of $146,963.25. Following the sale, the insider now directly owns 190,052 shares of the company’s stock, valued at $2,886,889.88. The disclosure for this sale can be found here. Insiders have sold 13,475 shares of company stock worth $205,133 over the last 90 days. 7.58% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Entrada Therapeutics

Several institutional investors have recently added to or reduced their stakes in TRDA. Wellington Management Group LLP grew its position in shares of Entrada Therapeutics by 2.6% during the 3rd quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company’s stock valued at $16,521,000 after acquiring an additional 26,144 shares during the period. Strs Ohio lifted its stake in Entrada Therapeutics by 792.6% in the fourth quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $363,000 after purchasing an additional 21,400 shares during the last quarter. Vanguard Group Inc. grew its holdings in Entrada Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after buying an additional 11,965 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Entrada Therapeutics in the first quarter valued at $79,000. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.